Updated Guidelines Aim to Refine Post-Mastectomy Radiation Therapy for Breast Cancer Patients

Three national cancer organizations have released updated guidelines on post-mastectomy radiation therapy (PMRT) for breast cancer patients. The new recommendations help doctors decide when PMRT is appropriate, based on the latest research and advances in treatment, and provide best practices for safe and effective care.

The guideline was jointly published by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), and the Society of Surgical Oncology (SSO) in their journals Practical Radiation Oncology, Journal of Clinical Oncology, and Annals of Surgical Oncology.

Over 100,000 people in the U.S. undergo mastectomy for breast cancer each year. PMRT is often recommended for patients at higher risk of recurrence, particularly those with cancer in the lymph nodes. Radiation after surgery helps destroy microscopic cancer cells that may remain, lowering the chance of the cancer returning and improving long-term survival.

“Radiation after mastectomy can significantly reduce the risk of recurrence for many patients with invasive breast cancer,” said Dr. Rachel B. Jimenez, co-chair of the guideline panel and radiation oncologist at Massachusetts General Hospital. “But the benefits depend on individual disease features and patient preferences, making personalized care essential.”

The updated guideline reflects:

• Better diagnostics to identify patients most likely to benefit.
• Improved radiation techniques that reduce side effects.
• Less invasive surgery and systemic therapies that enhance outcomes.

Main Recommendations Include:

• Node-positive disease (pN+): PMRT is generally recommended to reduce recurrence and mortality. Omission may be reasonable for select patients with very low risk.
• Node-negative disease: Recommended for higher-risk patients, such as those with large tumors (pT3-4) or younger age. Usually not needed for smaller tumors (pT1-2) unless multiple high-risk features are present.
• After neoadjuvant therapy: PMRT is advised for patients with advanced disease at diagnosis or with residual cancer after chemotherapy.
• Dosing and fractionation: Moderate hypofractionation is preferred, with conventional schedules reserved for select cases. A radiation “boost” may be added if residual disease is suspected.
• Treatment delivery: All patients should receive CT-based planning. Advanced techniques like IMRT, daily imaging, and breath-hold methods are recommended when appropriate to improve precision and reduce side effects.
• Shared decision-making: Physicians should involve patients and all members of the care team to weigh benefits and risks.

The recommendations were developed by a panel of radiation, medical, and surgical oncologists, a medical physicist, and a patient representative. They are based on a systematic review of studies published between 2005 and 2024. The guideline is endorsed by the American Society of Breast Surgeons and the Royal Australian and New Zealand College of Radiologists.

This update builds on earlier guidelines from 2001 and 2016, with the goal of providing clearer, more individualized recommendations for breast cancer care.